Literature DB >> 24302567

Chemoprevention of nonalcoholic fatty liver disease by dietary natural compounds.

Min-Hsiung Pan1, Ching-Shu Lai, Mei-Ling Tsai, Chi-Tang Ho.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) refers to a wide spectrum of liver disease that is not from excess alcohol consumption, but is often associated with obesity, type 2 diabetes, and metabolic syndrome. NAFLD pathogenesis is complicated and involves oxidative stress, lipotoxicity, mitochondrial damage, insulin resistance, inflammation, and excessive dietary fat intake, which increase hepatic lipid influx and de novo lipogenesis and impair insulin signaling, thus promoting hepatic triglyceride accumulation and ultimately NAFLD. Overproduction of proinflammatory adipokines from adipose tissue also affects hepatic metabolic function. Current NAFLD therapies are limited; thus, much attention has been focused on identification of potential dietary substances from fruits, vegetables, and edible plants to provide a new strategy for NAFLD treatment. Dietary natural compounds, such as carotenoids, omega-3-PUFAs, flavonoids, isothiocyanates, terpenoids, curcumin, and resveratrol, act through a variety of mechanisms to prevent and improve NAFLD. Here, we summarize and briefly discuss the currently known targets and signaling pathways as well as the role of dietary natural compounds that interfere with NAFLD pathogenesis.
© 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Chemoprevention; Dietary natural compounds; Nonalcoholic fatty liver disease

Mesh:

Substances:

Year:  2013        PMID: 24302567     DOI: 10.1002/mnfr.201300522

Source DB:  PubMed          Journal:  Mol Nutr Food Res        ISSN: 1613-4125            Impact factor:   5.914


  16 in total

Review 1.  Carotenoids and non-alcoholic fatty liver disease.

Authors:  Bahiddin Yilmaz; Kazim Sahin; Hande Bilen; Ibrahim H Bahcecioglu; Birdal Bilir; Sara Ashraf; Karim J Halazun; Omer Kucuk
Journal:  Hepatobiliary Surg Nutr       Date:  2015-06       Impact factor: 7.293

2.  Thymoquinone alleviates nonalcoholic fatty liver disease in rats via suppression of oxidative stress, inflammation, apoptosis.

Authors:  Azza S M Awad; Ekram N Abd Al Haleem; Wesam M El-Bakly; Mohie A Sherief
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-01-12       Impact factor: 3.000

Review 3.  Herbal medicines and nonalcoholic fatty liver disease.

Authors:  Hong Yao; Yu-Jie Qiao; Ya-Li Zhao; Xu-Feng Tao; Li-Na Xu; Lian-Hong Yin; Yan Qi; Jin-Yong Peng
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

4.  Acute oral treatment with resveratrol and Lactococcus Lactis Subsp. Lactis decrease body weight and improve liver proinflammatory markers in C57BL/6 mice.

Authors:  Keila Lopes Mendes; Deborah de Farias Lelis; Daniela Fernanda de Freitas; Luiz Henrique da Silveira; Alfredo Maurício Batista de Paula; André Luiz Sena Guimarães; Janaína Ribeiro Oliveira; Mariléia Chaves Andrade; Sérgio Avelino Mota Nobre; Sérgio Henrique Sousa Santos
Journal:  Mol Biol Rep       Date:  2021-02-14       Impact factor: 2.316

5.  Açaí (Euterpe oleracea Martius) supplementation in the diet during gestation and lactation attenuates liver steatosis in dams and protects offspring.

Authors:  Priscila O Barbosa; Melina O de Souza; Deuziane P D Paiva; Marcelo E Silva; Wanderson G Lima; Giovanna Bermano; Renata N Freitas
Journal:  Eur J Nutr       Date:  2019-07-05       Impact factor: 5.614

6.  Rimonabant Improves Oxidative/Nitrosative Stress in Mice with Nonalcoholic Fatty Liver Disease.

Authors:  Bojan Jorgačević; Dušan Mladenović; Milica Ninković; Milena Vesković; Vesna Dragutinović; Aleksandar Vatazević; Danijela Vučević; Rada Ješić Vukićević; Tatjana Radosavljević
Journal:  Oxid Med Cell Longev       Date:  2015-05-11       Impact factor: 6.543

Review 7.  Potential epigenetic mechanism in non-alcoholic Fatty liver disease.

Authors:  Chao Sun; Jian-Gao Fan; Liang Qiao
Journal:  Int J Mol Sci       Date:  2015-03-05       Impact factor: 5.923

Review 8.  Potential Biological Effects of (-)-Epigallocatechin-3-gallate on the Treatment of Nonalcoholic Fatty Liver Disease.

Authors:  Cheng Chen; Qian Liu; Lin Liu; Yi-Yang Hu; Qin Feng
Journal:  Mol Nutr Food Res       Date:  2017-10-12       Impact factor: 5.914

Review 9.  Epigenetic mechanisms underlying the link between non-alcoholic fatty liver diseases and nutrition.

Authors:  Joo Ho Lee; Simonetta Friso; Sang-Woon Choi
Journal:  Nutrients       Date:  2014-08-21       Impact factor: 5.717

10.  Pentoxifylline ameliorates non-alcoholic fatty liver disease in hyperglycaemic and dyslipidaemic mice by upregulating fatty acid β-oxidation.

Authors:  Jia-Hung Ye; Jung Chao; Ming-Ling Chang; Wen-Huang Peng; Hao-Yuan Cheng; Jiunn-Wang Liao; Li-Heng Pao
Journal:  Sci Rep       Date:  2016-09-09       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.